WOBURN, Mass., July 24, 2018 /PRNewswire/ — Among the “great minds” gathering at CannMed 2018 is the “Father of Cannabinoid Research,” Dr. Raphael Mechoulam (Hebrew University and Israel Ministry of Health) who discovered THC and identified the brain’s endocannabinoid system, which plays a role in mood, memory, and the sensation of pain.
“Research and development are needed to drive forward access to safe cannabis that is administered properly through educated practitioners. I encourage you to attend CannMed 2018 as we have developed it for that very purpose.” – Raphael Mechoulam, Ph.D.
CannMed 2018 will be held at The UCLA Luskin Conference Center at The University of California in Los Angeles, October 22-24, 2018. Today, Medicinal Genomics (MGC) and DASH announced CannMed’s full lineup and schedule featuring 31 presentations and 6 expert panel discussions in cannabis research, medicine, and cultivation worldwide.
Monday, October 22nd will be the pre-conference CME Workshop. Presentations begin on Tuesday, October 23, 2018 at 8:00AM, with a keynote address from Dr. Raphael Mechoulam. The rest of the morning’s presentations will focus on the Endocannabinoid System and Using Cannabis to Treat Epilepsy, Autism, and Other Inflammatory Disorders and will include presentations by Dr. John Gaitanis (Tufts Medical Center), Dr. Bonni Goldstein (Canna-Centers), and Dr. Ethan Russo(International Cannabis & Cannabinoids Institute). A panel of medical experts on Cannabis as a Treatment for Alzheimer’s Disease, led by Dr. Jeffrey Chen of UCLA will conclude the morning presentations.
Two afternoon tracks are scheduled. Track 1, Cannabis in Relation to Pain Relief and a Potential Alternative to Opioids, is launched by Dr. Staci Gruber (Harvard Medical School) and concludes with a panel discussion on Cannabis and Opioids, led by Dr. Dustin Sulak (Healer.com). Track 2 examines Cannabis Genetics and Integrating Blockchain Technology into the Cannabis Industry, featuring Jonathan Page, Ph.D. (Anandia Labs) and Kevin McKernan (Medicinal Genomics). The day concludes with an opportunity to engage with a panel of cannabis industry influencers.
The Wednesday, October 24, 2018 at 8:00AM morning session focuses on Cannabis Regulations in the United States and abroad with Dr. Michael Dor (Israel Ministry of Health) and a panel of notable regulatory leaders from state, national, and international levels, led by Catherine Jacobson (Tilray).
Cannabis Cultivation highlights the first Wednesday afternoon session with a presentation by Jeffrey Raber Ph.D. (The Werc Shop) and a panel of cultivation specialists led by Katya Boudko (Canopy Growth). CannMed 2018 finishes strong with a session focused on Treating Cancer Patients with Cannabis, featuring a presentation from David Meiri Ph.D. (Technion-Israel Institute of Technology)and an extended cancer-focused panel discussion led by Dr. Joe D. Goldstrich (Natural State Healthcare).
For the full scoop and CannMed 2018 schedule, visit www.cannmedevents.com.
About CannMed 2018
CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world’s top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis, including epilepsy, pain, traumatic brain injury, cancer, autism, and more. Physicians and clinicians will also share compelling case studies and clinical pearls they have collected through their experience treating patients with cannabis. Laboratory professionals will also share their revolutionary technologies when it comes to cannabinoid and terpenoid extraction, delivery methods, and quality and safety testing.
About Medicinal Genomics
Medicinal Genomics (MGC) uses its unmatched knowledge into the cannabis genome and the microbes that impact cannabis plants to create a diverse set of testing solutions that improve crop yield, accelerate breeding programs, and ensure product safety. Many of the top cannabis testing labs trust MGC’s PathoSEEK Microbial Safety Testing Platform to detect harmful pathogens before cannabis products are sold to consumer and patients. Cannabis cultivators also turn to MGC to provide information about their strain’s genetics, which can be used to protect IP and drive marker-assisted breeding programs. For more information about MGC, visit www.medicinalgenomics.com.
Leave a Reply